Effects of CETP inhibition on triglyceride-rich lipoprotein composition and apoB-48 metabolism

Cholesteryl ester transfer protein (CETP) facilitates the transfer of HDL cholesteryl ester to triglyceride-rich lipoproteins (TRL). This study aimed to determine the effects of CETP inhibition with torcetrapib on TRL composition and apoB-48 metabolism. Study subjects with low HDL cholesterol (<4...

Ausführliche Beschreibung

Gespeichert in:

Bibliographische Detailangaben
Veröffentlicht in:	Journal of lipid research Jg. 53; H. 6; S. 1190 - 1199
Hauptverfasser:	Diffenderfer, Margaret R, Brousseau, Margaret E, Millar, John S, Barrett, P Hugh R, Nartsupha, Chorthip, Schaefer, Peter M, Wolfe, Megan L, Dolnikowski, Gregory G, Rader, Daniel J, Schaefer, Ernst J
Format:	Journal Article
Sprache:	Englisch
Veröffentlicht:	United States Elsevier 01.06.2012
Schlagworte:	apolipoprotein Apolipoprotein B-48 - blood Apolipoprotein B-48 - metabolism Cholesterol Ester Transfer Proteins - antagonists & inhibitors cholesteryl ester transfer protein Female Humans Kinetics lipoprotein kinetics Lipoproteins - blood Lipoproteins - chemistry Lipoproteins - metabolism Male Middle Aged postprandial metabolism Quinolines - pharmacology torcetrapib Triglycerides
ISSN:	1539-7262, 0022-2275, 1539-7262
Online-Zugang:	Volltext
Tags:	Tag hinzufügen Keine Tags, Fügen Sie den ersten Tag hinzu!

Abstract	Cholesteryl ester transfer protein (CETP) facilitates the transfer of HDL cholesteryl ester to triglyceride-rich lipoproteins (TRL). This study aimed to determine the effects of CETP inhibition with torcetrapib on TRL composition and apoB-48 metabolism. Study subjects with low HDL cholesterol (<40 mg/dl), either untreated (n = 9) or receiving atorvastatin 20 mg daily (n = 9), received placebo for 4 weeks, followed by torcetrapib 120 mg once daily for the next 4 weeks. A subset of the subjects not treated with atorvastatin participated in a third phase (n = 6), in which they received torcetrapib 120 mg twice daily for an additional 4 weeks. At the end of each phase, all subjects received a primed-constant infusion of [5,5,5-(2)H(3)]L-leucine, while in the constantly fed state, to determine the kinetics of TRL apoB-48 and TRL composition. Relative to placebo, torcetrapib markedly reduced TRL CE levels in all groups (≥-69%; P < 0.005). ApoB-48 pool size (PS) and production rate (PR) decreased in the nonatorvastatin once daily (PS: -49%, P = 0.007; PR: -49%, P = 0.005) and twice daily (PS: -30%, P = 0.01; PR: -27%, P = 0.13) cohorts. In the atorvastatin cohort, apoB-48 PS and PR, which were already lowered by atorvastatin, did not change with torcetrapib. Our findings indicate that CETP inhibition reduced plasma apoB-48 concentrations by reducing apoB-48 production but did not have this effect in subjects already treated with atorvastatin.
AbstractList	Cholesteryl ester transfer protein (CETP) facilitates the transfer of HDL cholesteryl ester to triglyceride-rich lipoproteins (TRL). This study aimed to determine the effects of CETP inhibition with torcetrapib on TRL composition and apoB-48 metabolism. Study subjects with low HDL cholesterol (<40 mg/dl), either untreated (n = 9) or receiving atorvastatin 20 mg daily (n = 9), received placebo for 4 weeks, followed by torcetrapib 120 mg once daily for the next 4 weeks. A subset of the subjects not treated with atorvastatin participated in a third phase (n = 6), in which they received torcetrapib 120 mg twice daily for an additional 4 weeks. At the end of each phase, all subjects received a primed-constant infusion of [5,5,5-2H3]L-leucine, while in the constantly fed state, to determine the kinetics of TRL apoB-48 and TRL composition. Relative to placebo, torcetrapib markedly reduced TRL CE levels in all groups (≥−69%; P < 0.005). ApoB-48 pool size (PS) and production rate (PR) decreased in the nonatorvastatin once daily (PS: −49%, P = 0.007; PR: −49%, P = 0.005) and twice daily (PS: −30%, P = 0.01; PR: −27%, P = 0.13) cohorts. In the atorvastatin cohort, apoB-48 PS and PR, which were already lowered by atorvastatin, did not change with torcetrapib. Our findings indicate that CETP inhibition reduced plasma apoB-48 concentrations by reducing apoB-48 production but did not have this effect in subjects already treated with atorvastatin. Cholesteryl ester transfer protein (CETP) facilitates the transfer of HDL cholesteryl ester to triglyceride-rich lipoproteins (TRL). This study aimed to determine the effects of CETP inhibition with torcetrapib on TRL composition and apoB-48 metabolism. Study subjects with low HDL cholesterol (<40 mg/dl), either untreated (n = 9) or receiving atorvastatin 20 mg daily (n = 9), received placebo for 4 weeks, followed by torcetrapib 120 mg once daily for the next 4 weeks. A subset of the subjects not treated with atorvastatin participated in a third phase (n = 6), in which they received torcetrapib 120 mg twice daily for an additional 4 weeks. At the end of each phase, all subjects received a primed-constant infusion of [5,5,5-(2)H(3)]L-leucine, while in the constantly fed state, to determine the kinetics of TRL apoB-48 and TRL composition. Relative to placebo, torcetrapib markedly reduced TRL CE levels in all groups (≥-69%; P < 0.005). ApoB-48 pool size (PS) and production rate (PR) decreased in the nonatorvastatin once daily (PS: -49%, P = 0.007; PR: -49%, P = 0.005) and twice daily (PS: -30%, P = 0.01; PR: -27%, P = 0.13) cohorts. In the atorvastatin cohort, apoB-48 PS and PR, which were already lowered by atorvastatin, did not change with torcetrapib. Our findings indicate that CETP inhibition reduced plasma apoB-48 concentrations by reducing apoB-48 production but did not have this effect in subjects already treated with atorvastatin.Cholesteryl ester transfer protein (CETP) facilitates the transfer of HDL cholesteryl ester to triglyceride-rich lipoproteins (TRL). This study aimed to determine the effects of CETP inhibition with torcetrapib on TRL composition and apoB-48 metabolism. Study subjects with low HDL cholesterol (<40 mg/dl), either untreated (n = 9) or receiving atorvastatin 20 mg daily (n = 9), received placebo for 4 weeks, followed by torcetrapib 120 mg once daily for the next 4 weeks. A subset of the subjects not treated with atorvastatin participated in a third phase (n = 6), in which they received torcetrapib 120 mg twice daily for an additional 4 weeks. At the end of each phase, all subjects received a primed-constant infusion of [5,5,5-(2)H(3)]L-leucine, while in the constantly fed state, to determine the kinetics of TRL apoB-48 and TRL composition. Relative to placebo, torcetrapib markedly reduced TRL CE levels in all groups (≥-69%; P < 0.005). ApoB-48 pool size (PS) and production rate (PR) decreased in the nonatorvastatin once daily (PS: -49%, P = 0.007; PR: -49%, P = 0.005) and twice daily (PS: -30%, P = 0.01; PR: -27%, P = 0.13) cohorts. In the atorvastatin cohort, apoB-48 PS and PR, which were already lowered by atorvastatin, did not change with torcetrapib. Our findings indicate that CETP inhibition reduced plasma apoB-48 concentrations by reducing apoB-48 production but did not have this effect in subjects already treated with atorvastatin. Cholesteryl ester transfer protein (CETP) facilitates the transfer of HDL cholesteryl ester to triglyceride-rich lipoproteins (TRL). This study aimed to determine the effects of CETP inhibition with torcetrapib on TRL composition and apoB-48 metabolism. Study subjects with low HDL cholesterol (<40 mg/dl), either untreated (n = 9) or receiving atorvastatin 20 mg daily (n = 9), received placebo for 4 weeks, followed by torcetrapib 120 mg once daily for the next 4 weeks. A subset of the subjects not treated with atorvastatin participated in a third phase (n = 6), in which they received torcetrapib 120 mg twice daily for an additional 4 weeks. At the end of each phase, all subjects received a primed-constant infusion of [5,5,5-(2)H(3)]L-leucine, while in the constantly fed state, to determine the kinetics of TRL apoB-48 and TRL composition. Relative to placebo, torcetrapib markedly reduced TRL CE levels in all groups (≥-69%; P < 0.005). ApoB-48 pool size (PS) and production rate (PR) decreased in the nonatorvastatin once daily (PS: -49%, P = 0.007; PR: -49%, P = 0.005) and twice daily (PS: -30%, P = 0.01; PR: -27%, P = 0.13) cohorts. In the atorvastatin cohort, apoB-48 PS and PR, which were already lowered by atorvastatin, did not change with torcetrapib. Our findings indicate that CETP inhibition reduced plasma apoB-48 concentrations by reducing apoB-48 production but did not have this effect in subjects already treated with atorvastatin.
Author	Diffenderfer, Margaret R Barrett, P Hugh R Brousseau, Margaret E Schaefer, Ernst J Millar, John S Dolnikowski, Gregory G Wolfe, Megan L Nartsupha, Chorthip Schaefer, Peter M Rader, Daniel J
Author_xml	– sequence: 1 givenname: Margaret R surname: Diffenderfer fullname: Diffenderfer, Margaret R organization: Lipid Metabolism Laboratory, Jean Mayer USDA Human Nutrition Research Center on Aging at Tufts University, Boston, MA, USA – sequence: 2 givenname: Margaret E surname: Brousseau fullname: Brousseau, Margaret E – sequence: 3 givenname: John S surname: Millar fullname: Millar, John S – sequence: 4 givenname: P Hugh R surname: Barrett fullname: Barrett, P Hugh R – sequence: 5 givenname: Chorthip surname: Nartsupha fullname: Nartsupha, Chorthip – sequence: 6 givenname: Peter M surname: Schaefer fullname: Schaefer, Peter M – sequence: 7 givenname: Megan L surname: Wolfe fullname: Wolfe, Megan L – sequence: 8 givenname: Gregory G surname: Dolnikowski fullname: Dolnikowski, Gregory G – sequence: 9 givenname: Daniel J surname: Rader fullname: Rader, Daniel J – sequence: 10 givenname: Ernst J surname: Schaefer fullname: Schaefer, Ernst J
BackLink	https://www.ncbi.nlm.nih.gov/pubmed/22474066$$D View this record in MEDLINE/PubMed
BookMark	eNpNkM1LxDAQxYMo6q6evEuPXqqZJm2aoy7rByh6WK-WfEw0S9vUpHvwv7e6KsKDGYY3v2HejOz2oUdCToCeA0h-sW7j-QMFWQq6Qw6hZDIXRVXs_usPyCylNaXAeQX75KAouOC0qg7Jy9I5NGPKgssWy9VT5vs3r_3oQ59NGqN_bT8MRm8xj968Za0fwhDDiL7PTOiGkLZm1dtMDeEq53XW4ah0aH3qjsieU23C4586J8_Xy9XiNr9_vLlbXN7nhks25kwL0GClZGXJuROSC1WokoHVrKJQ11oiUkEllKidrGnNnEBTC1kpDQrZnNxtuTaodTNE36n40QTlm-9BiK-NiqM3LTZOSfO17WwJXIPTEibx2k4RmtKqiXW2ZU1vvm8wjU3nk8G2VT2GTWqAQiG4LKZ05-T0x7rRHdq_w7_5sk-vz329
CitedBy_id	crossref_primary_10_1194_jlr_M036509 crossref_primary_10_1002_lipd_12271 crossref_primary_10_1194_jlr_E027334 crossref_primary_10_1007_s10557_021_07168_0 crossref_primary_10_7555_JBR_37_20230223 crossref_primary_10_1016_j_atherosclerosis_2014_05_935 crossref_primary_10_1016_j_plipres_2014_07_002 crossref_primary_10_1097_MOL_0b013e3283612454 crossref_primary_10_1161_ATVBAHA_115_305614 crossref_primary_10_1016_j_clinthera_2015_08_001 crossref_primary_10_1517_13543784_2014_922950
ContentType	Journal Article
DBID	CGR CUY CVF ECM EIF NPM 7X8 DOA
DOI	10.1194/jlr.M019570
DatabaseName	Medline MEDLINE MEDLINE (Ovid) MEDLINE MEDLINE PubMed MEDLINE - Academic DOAJ Directory of Open Access Journals
DatabaseTitle	MEDLINE Medline Complete MEDLINE with Full Text PubMed MEDLINE (Ovid) MEDLINE - Academic
DatabaseTitleList	MEDLINE - Academic MEDLINE
Database_xml	– sequence: 1 dbid: DOA name: DOAJ Directory of Open Access Journals url: https://www.doaj.org/ sourceTypes: Open Website – sequence: 2 dbid: NPM name: PubMed url: http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=PubMed sourceTypes: Index Database – sequence: 3 dbid: 7X8 name: MEDLINE - Academic url: https://search.proquest.com/medline sourceTypes: Aggregation Database
DeliveryMethod	fulltext_linktorsrc
Discipline	Anatomy & Physiology Chemistry
EISSN	1539-7262
EndPage	1199
ExternalDocumentID	oai_doaj_org_article_fa9c3f7efd514b1fb91b9148d019c5da 22474066
Genre	Research Support, U.S. Gov't, Non-P.H.S Controlled Clinical Trial Research Support, Non-U.S. Gov't Journal Article Research Support, N.I.H., Extramural
GrantInformation_xml	– fundername: NCRR NIH HHS grantid: M01 RR000040 – fundername: NCRR NIH HHS grantid: UL1 RR024134 – fundername: NCRR NIH HHS grantid: UL-1RR024134 – fundername: NHLBI NIH HHS grantid: P50 HL083813 – fundername: NCRR NIH HHS grantid: M01-RR00040 – fundername: NHLBI NIH HHS grantid: P50 HL083813-01
GroupedDBID	--- -~X .55 .GJ 0R~ 0VX 18M 29K 2WC 34G 39C 4.4 53G 5GY 5RE 5VS AAEDW AAFWJ AALRI AAXUO AAYOK ABCQX ABOCM ACCCW ACGFO ACKIV ACNCT ACPRK ADBBV ADVLN AENEX AEXQZ AFFNX AFOSN AI. AITUG AKRWK ALMA_UNASSIGNED_HOLDINGS AMRAJ AOIJS BAWUL BTFSW C1A CGR CS3 CUY CVF D-I DIK DU5 E3Z EBS ECM EIF EJD F5P FDB FRP GROUPED_DOAJ GX1 H13 HH5 HYE H~9 J5H KQ8 L7B MVM NPM OK1 P2P RHF RHI ROL RPM TBC TR2 TWZ VH1 W8F WH7 WOQ X7M YHG YKV ZGI ZXP ~KM 7X8 AAYWO ACVFH ADCNI AEUPX AFPKN AFPUW AIGII AKBMS AKYEP
ID	FETCH-LOGICAL-c493t-3b71b1d9935544f7947a2a531db360188b9ee070915ebf98083f7ec8796ab1ae3
IEDL.DBID	DOA
ISICitedReferencesCount	11
ISICitedReferencesURI	http://www.webofscience.com/api/gateway?GWVersion=2&SrcApp=Summon&SrcAuth=ProQuest&DestLinkType=CitingArticles&DestApp=WOS_CPL&KeyUT=000303913200016&url=https%3A%2F%2Fcvtisr.summon.serialssolutions.com%2F%23%21%2Fsearch%3Fho%3Df%26include.ft.matches%3Dt%26l%3Dnull%26q%3D
ISSN	1539-7262 0022-2275
IngestDate	Fri Oct 03 12:51:42 EDT 2025 Fri Sep 05 10:26:30 EDT 2025 Thu Jan 02 22:56:49 EST 2025
IsDoiOpenAccess	true
IsOpenAccess	true
IsPeerReviewed	true
IsScholarly	true
Issue	6
Language	English
LinkModel	DirectLink
MergedId	FETCHMERGED-LOGICAL-c493t-3b71b1d9935544f7947a2a531db360188b9ee070915ebf98083f7ec8796ab1ae3
Notes	ObjectType-Article-2 SourceType-Scholarly Journals-1 ObjectType-Feature-1 content type line 23
OpenAccessLink	https://doaj.org/article/fa9c3f7efd514b1fb91b9148d019c5da
PMID	22474066
PQID	1012749215
PQPubID	23479
PageCount	10
ParticipantIDs	doaj_primary_oai_doaj_org_article_fa9c3f7efd514b1fb91b9148d019c5da proquest_miscellaneous_1012749215 pubmed_primary_22474066
PublicationCentury	2000
PublicationDate	2012-06-01
PublicationDateYYYYMMDD	2012-06-01
PublicationDate_xml	– month: 06 year: 2012 text: 2012-06-01 day: 01
PublicationDecade	2010
PublicationPlace	United States
PublicationPlace_xml	– name: United States
PublicationTitle	Journal of lipid research
PublicationTitleAlternate	J Lipid Res
PublicationYear	2012
Publisher	Elsevier
Publisher_xml	– name: Elsevier
References	22496386 - J Lipid Res. 2012 Jun;53(6):1039-41
References_xml	– reference: 22496386 - J Lipid Res. 2012 Jun;53(6):1039-41
SSID	ssj0014461
Score	2.113573
Snippet	Cholesteryl ester transfer protein (CETP) facilitates the transfer of HDL cholesteryl ester to triglyceride-rich lipoproteins (TRL). This study aimed to...
SourceID	doaj proquest pubmed
SourceType	Open Website Aggregation Database Index Database
StartPage	1190
SubjectTerms	apolipoprotein Apolipoprotein B-48 - blood Apolipoprotein B-48 - metabolism Cholesterol Ester Transfer Proteins - antagonists & inhibitors cholesteryl ester transfer protein Female Humans Kinetics lipoprotein kinetics Lipoproteins - blood Lipoproteins - chemistry Lipoproteins - metabolism Male Middle Aged postprandial metabolism Quinolines - pharmacology torcetrapib Triglycerides
Title	Effects of CETP inhibition on triglyceride-rich lipoprotein composition and apoB-48 metabolism
URI	https://www.ncbi.nlm.nih.gov/pubmed/22474066 https://www.proquest.com/docview/1012749215 https://doaj.org/article/fa9c3f7efd514b1fb91b9148d019c5da
Volume	53
WOSCitedRecordID	wos000303913200016&url=https%3A%2F%2Fcvtisr.summon.serialssolutions.com%2F%23%21%2Fsearch%3Fho%3Df%26include.ft.matches%3Dt%26l%3Dnull%26q%3D
hasFullText	1
inHoldings	1
isFullTextHit
isPrint
link	http://cvtisr.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwrV3PS8MwFH6oCHoRfzt_EUG8Vdc1aZrjHA4POnZQ2cmSNAlWtnZsneB_70vaiRfxIoQe2kND3kvzfc2X7wFcxrHgstOmgTVtFlAnc5U8pkHGDYsMAtrQV2t4eeCDQTIaieGPUl9OE1bbA9cDd2OlyCLLjdW4tKvQKhFio4lGbJIx7aERop4lmWr2D5DkhEuf8E6Hs-ZkHjL2m_fx7PrRHZNz9Ym9T__v4NIvMv1t2GrQIenWvdqBFVPswl63QGY8-SRXxOs1_Y_wXdjoLWu17cFrbUI8J6UlvbunIcmLt1x5NRbBViEFH39mmGzaBPjheyPjfFp6i4a8IE5V3ki3iCw0kdPyNqAJmZgKM2Sczyf78Ny_e-rdB03lhCCjIqqCSPFQhVo483RKLc45DIjE6aZVhAwsSZQwBie7CJlRViSIw3CIs4SLWKpQmugA1oqyMEdAOD6hyOmQCCrKLFMxb-tISqZ0RJm0Lbh1Y5hOa3OM1NlV-xsYxLQJYvpXEFtwsYxAiiPn9ixkYcrF3CnQkDcLTJkWHNah-X4Vog-OeCQ-_o8unMAmYqFOrQI7hbVqtjBnsJ59VPl8dg6rfJSc-xzD62D4-AU9Z9Wc
linkProvider	Directory of Open Access Journals
openUrl	ctx_ver=Z39.88-2004&ctx_enc=info%3Aofi%2Fenc%3AUTF-8&rfr_id=info%3Asid%2Fsummon.serialssolutions.com&rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&rft.genre=article&rft.atitle=Effects+of+CETP+inhibition+on+triglyceride-rich+lipoprotein+composition+and+apoB-48+metabolism&rft.jtitle=Journal+of+lipid+research&rft.au=Margaret+R.+Diffenderfer&rft.au=Margaret+E.+Brousseau&rft.au=John+S.+Millar&rft.au=P.Hugh+R.+Barrett&rft.date=2012-06-01&rft.pub=Elsevier&rft.issn=0022-2275&rft.volume=53&rft.issue=6&rft.spage=1190&rft.epage=1199&rft_id=info:doi/10.1194%2Fjlr.M019570&rft.externalDBID=DOA&rft.externalDocID=oai_doaj_org_article_fa9c3f7efd514b1fb91b9148d019c5da
thumbnail_l	http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/lc.gif&issn=1539-7262&client=summon
thumbnail_m	http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/mc.gif&issn=1539-7262&client=summon
thumbnail_s	http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/sc.gif&issn=1539-7262&client=summon